ES2038215T3 - Medicamentos. - Google Patents

Medicamentos.

Info

Publication number
ES2038215T3
ES2038215T3 ES198787900101T ES87900101T ES2038215T3 ES 2038215 T3 ES2038215 T3 ES 2038215T3 ES 198787900101 T ES198787900101 T ES 198787900101T ES 87900101 T ES87900101 T ES 87900101T ES 2038215 T3 ES2038215 T3 ES 2038215T3
Authority
ES
Spain
Prior art keywords
pct
sec
date
medicines
pub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787900101T
Other languages
English (en)
Inventor
Hansjorg Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Application granted granted Critical
Publication of ES2038215T3 publication Critical patent/ES2038215T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/08Ethers or acetals acyclic, e.g. paraformaldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Procedimiento para preparar un medicamento (activo antitumoralmente) que actúa sinérgicamente, caracterizado porque se mezcla u homogeneiza 1 parte en peso de por lo menos un compuesto de fórmula general R- Y - PO2 - X-R1 en donde R significa un radical de hidrocarburo saturado o insaturado con 12 hasta 24 átomos de C, que también puede estar sustituido con halógeno, X significa un átomo de oxígeno, NH o NR2 e Y es un átomo de oxígeno o NH, R1 es un grupo alquilo C1- C8, o en donde R1 representa un grupo alquilo C2-C8, queestá insaturado y/o sustituido con halógeno, amino, alquil C1-C6-amino, di-alquil C1-C6-amino, tri-alquil C1-C6-amino, hidroxi, carboxi, cicloalquilo C3-C8 o fenilo, y en donde R1, además, puede significar también 2-t-butil-oxi-carbonil-amino-etilo, 2-t-butil-oxi-carbonil-etilo, 2,3-isopropiliden-dioxi-propilo(1), 2,3-di-bencil-oxi-propilo-(1), 1,3-di-bencil- oxipropilo-(2) o N-alquil C1-C6-amino-alquilo C2-C6, cuando X es un átomo de oxígeno, y en donde R1 puede significar además 2,3-di-hidroxi-propilo-(1), cuando X es el grupo NH, y R2 es un grupo 2,3-di-hidroxi-propilo-(1), un grupo alquilo C1-C8 o un grupo alquilo C2-C8 que está insaturado y/o sustituido con halógeno, amino, alquil C1-C6-amino, di-alquil C1-C6-amino, tri-alquil C1- C6-amino, hidroxi, carboxi, cicloalquilo C3-C8 o fenilo, o de por lo menos un compuesto de fórmula general R -Y-PO2 - X-R1 en donde R significa un radical de hidrocarburo saturado o insaturado con 12 a 24 átomos de C, que también puede estar sustituido con halógeno, X es un átomo de oxígeno, NH o NR2 e Yesunátomo de oxígeno o NH, el radical R1 (1) representa un grupo alquilo C1-C8, un grupo alquilo C3-C8 insaturado, que está sustituido con halógeno, amino, alquil C1-C6-amino, di-alquil C1-C6-amino, tri-alquil C1-C6-amino, hidroxi, carboxi, cicloalquilo C3-C8 o fenilo, o (2) representa un grupo alquilo C2, queestá sustituido con halógeno, hidroxi, carboxi, cicloalquilo C3-C8 o fenilo, o (3) representa un grupo alquilo C2 insaturado, que está sustituido con di-alquil C1-C6-amino, tri-alquil C1-C6-amino, carboxi, cicloalquilo C3-C8 o fenilo, o (4) representa un grupo alquilo C2, queestá sustituido con amino, alquil C1-C6-amino, di-alquil C1-C6- amino o tri-alquil C1-C6-amino, caso de X signifique oxígeno, NH o NR2 e Y signifique el grupo NHo caso de X signifique el grupo NH o NR2 e Ysignifiqueoxígeno, y R tenga los significados indicados, o (5) puede significar -t-butil-oxi-carbonil-amino-etilo, 2-t-butil-oxi-carbonil-etilo, 2,3-isopropiliden-dioxi-propilo-(1), 2,3-di-bencil-oxi-propilo-(1), 1,3-di-bencil-oxipropilo-(2) o N-alquil C1-C6-amino-alquilo C2-C6, cuando X es un átomo de oxígeno e Y y R tienen los significados indicados, o (6) puede significar 2,3-di-hidroxi-propilo-(1), cuando X es el grupo NH e Y y R tienen los significados indicados y R2 representa un grupo 2,3-di-hidroxi-propilo-(1), un grupo alquilo C1-C8, o un grupo alquilo C2-C8 que está insaturado y/o sustituido con halógeno, amino, alquil C1-C6-amino, dialquil C1-C6-amino, tri-alquil C1-C6-amino, hidroxi, carboxi, cicloalquilo C3-C8 o fenilo, en donde R, R1, R2, X e Y tienen los significados indicados y los compuestos I y I'' se pueden presentar también en forma de sus sales fisiológicamente compatibles,con 1 a 30 partes en peso de por lo menos un glicerol-éter de fórmula II H2 C - O-R3 j H C- O- R4 j H2 C - OH en la que uno de los radicales R3 y R4 significa un grupo alquilo con 2 a 12 átomos de C y el otro radical significa un átomo de H, o de una mezcla de tales glicerol-éteres, así como eventualmente 1 a 30 partes en peso de agua y eventualmente otras sustancias de vehículo y/o diluyentes o coadyuvantes, a temperaturas entre 20 y 120º C, y eventualmente la mezcla así obtenida, para la producción de preparados, que en una unidad de dosificación contienen de 5 a 2.000 mg de sustancia activa de fórmula I o I'', se vierte dentro de cavidades vacías de tamaño adecuado o se envasa en cápsulas de tamaño adecuado o se granula y luego eventualmente, con adición de otras sustancias coadyuvantes usuales, se prensa a la forma de tabletas.
ES198787900101T 1985-12-04 1986-12-04 Medicamentos. Expired - Lifetime ES2038215T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3542893 1985-12-04
DE3606631 1986-02-28

Publications (1)

Publication Number Publication Date
ES2038215T3 true ES2038215T3 (es) 1993-07-16

Family

ID=25838509

Family Applications (2)

Application Number Title Priority Date Filing Date
ES198787900101T Expired - Lifetime ES2038215T3 (es) 1985-12-04 1986-12-04 Medicamentos.
ES198686906829T Expired - Lifetime ES2032755T3 (es) 1985-12-04 1986-12-04 Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES198686906829T Expired - Lifetime ES2032755T3 (es) 1985-12-04 1986-12-04 Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral.

Country Status (15)

Country Link
US (2) US4837023A (es)
EP (4) EP0225608A3 (es)
JP (2) JPH0637393B2 (es)
AT (2) ATE64529T1 (es)
CA (2) CA1280369C (es)
DE (4) DE3641379A1 (es)
DK (2) DK172954B1 (es)
ES (2) ES2038215T3 (es)
FI (2) FI873363A (es)
GR (2) GR3002487T3 (es)
HU (2) HU203201B (es)
IE (2) IE59778B1 (es)
NO (2) NO174877C (es)
PT (2) PT83873B (es)
WO (2) WO1987003478A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916884A (en) * 1985-12-04 1999-06-29 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing a mixture of phosphorus compounds and alkylglycerols
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
DE69026991T2 (de) * 1989-08-10 1997-01-16 Sandoz Ag Phospholipide zur Behandlung der multiplen Sklerose
US5182271A (en) * 1989-08-10 1993-01-26 Sandoz Ltd. Thioether, keto-ester and alkyl phospholipids useful in treating multiple sclerosis
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
US5506217A (en) * 1991-04-25 1996-04-09 The University Of British Columbia Phosphonates as anti-cancer agents
DE59208905D1 (de) * 1991-07-04 1997-10-23 Asta Medica Ag Verfahren zur Herstellung von Alkylphosphocholinen und Reinherstellung derselben
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE4222910A1 (de) * 1992-07-11 1994-01-13 Asta Medica Ag Neue Phospholipidderivate
DE4235911A1 (de) * 1992-10-23 1994-04-28 Asta Medica Ag Stabilisierte Hexadecylphosphocholinlösungen in Glycerinalkylethern
AU7044894A (en) * 1993-06-10 1995-01-03 University Of North Carolina At Chapel Hill, The (phospho)lipids for combatting hepatitis b virus infection
CA2171281C (en) 1993-09-09 1998-12-29 Romeo Rang Immunomodulating compositions from bile
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5962437A (en) * 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
AU1573495A (en) * 1995-02-10 1996-08-27 University Of British Columbia, The {4-hexadecyl-3-methoxy-butyl} phosphonic acid and its protienconjugates useful as anti-cancer agents
WO1996028175A1 (en) 1995-03-16 1996-09-19 Imutec Pharma Inc. Immunomodulating compositions from bile for the treatment of immune system disorders
KR100499190B1 (ko) * 1996-03-29 2006-04-17 교와 핫꼬 고교 가부시끼가이샤 육모제
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
SE9701912D0 (sv) * 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US7582678B2 (en) * 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
HUP0004363A3 (en) * 1998-01-22 2002-12-28 Zentaris Gmbh Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
EP1397326A2 (en) * 2001-05-29 2004-03-17 Koninklijke Philips Electronics N.V. Metal-ceramic bond
WO2003021959A1 (en) * 2001-08-31 2003-03-13 Thomson Licensing Sa Sequence counter for an audio visual stream
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
PL1962862T3 (pl) 2005-12-19 2014-01-31 Aeterna Zentaris Gmbh Pochodne alkilofosfolipidów o ograniczonej cytotoksyczności i ich zastosowania
ES2391226T3 (es) * 2006-12-20 2012-11-22 Alphaptose Gmbh Forma farmacéutica tópica que comprende compuestos de glicerol tri-sustituido
JP2011057647A (ja) * 2009-09-14 2011-03-24 Adeka Corp 化粧料
KR102055395B1 (ko) 2011-06-24 2019-12-12 쥐알아이 바이오,아이엔씨. 염증 질환의 예방 및 치료
CN102491994B (zh) * 2011-12-07 2014-10-15 宁波九胜创新医药科技有限公司 一种胆碱磷酸烷基酯的制备方法
WO2016094226A1 (en) * 2014-12-09 2016-06-16 Glycoregimmune, Inc. Prevention and treatment of inflammatory conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3225227A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Derivate des n.n-bis-(2-chlor-aethyl)-phosphorsaeureamids
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds

Also Published As

Publication number Publication date
EP0225608A3 (de) 1987-10-28
US5049552A (en) 1991-09-17
EP0230575A2 (de) 1987-08-05
JPS63501719A (ja) 1988-07-14
DK393187A (da) 1987-07-28
NO174877C (no) 1994-07-27
CA1338627C (en) 1996-10-01
HUT44431A (en) 1988-03-28
EP0248062A1 (de) 1987-12-09
WO1987003478A2 (fr) 1987-06-18
ATE64529T1 (de) 1991-07-15
DK172954B1 (da) 1999-10-18
FI873363A0 (fi) 1987-08-03
NO175620B (es) 1994-08-01
GR3002487T3 (en) 1992-12-30
PT83873B (pt) 1989-01-17
WO1987003480A2 (en) 1987-06-18
EP0225608A2 (de) 1987-06-16
EP0248062B1 (de) 1992-05-06
HUT44441A (en) 1988-03-28
PT83873A (de) 1987-01-01
DE3641379A1 (de) 1987-09-03
DK393187D0 (da) 1987-07-28
GR3005168T3 (es) 1993-05-24
PT83872A (de) 1987-01-01
IE863177L (en) 1987-06-04
NO175620C (no) 1994-11-09
IE863176L (en) 1987-06-04
NO873243D0 (no) 1987-08-03
WO1987003478A3 (fr) 1987-09-24
DK398587D0 (da) 1987-07-30
NO873244D0 (no) 1987-08-03
US4837023A (en) 1989-06-06
HU208143B (en) 1993-08-30
EP0248047B1 (de) 1991-06-19
ATE75608T1 (de) 1992-05-15
FI873363A (fi) 1987-08-03
JP2857084B2 (ja) 1999-02-10
CA1280369C (en) 1991-02-19
ES2032755T3 (es) 1993-03-01
DE3679908D1 (de) 1991-07-25
IE59778B1 (en) 1994-04-06
EP0248047A1 (de) 1987-12-09
JPH0859677A (ja) 1996-03-05
DE19375061I2 (de) 2008-11-20
NO174877B (no) 1994-04-18
DE3641491A1 (de) 1987-09-17
IE59777B1 (en) 1994-04-06
EP0230575A3 (de) 1987-12-02
HU203201B (en) 1991-06-28
WO1987003480A3 (fr) 1988-02-25
FI873364A (fi) 1987-08-03
PT83872B (pt) 1989-01-17
FI873364A0 (fi) 1987-08-03
JPH0637393B2 (ja) 1994-05-18
NO873243L (no) 1987-10-02
DK398587A (da) 1987-07-30
NO873244L (no) 1987-10-01

Similar Documents

Publication Publication Date Title
ES2038215T3 (es) Medicamentos.
DE3887513D1 (de) Chemische formulierungen.
FI830100A0 (fi) Nya 6-substituerade s-triazolo /3,4-a/ ftalazinderivat
DE3668129D1 (de) Xy-tisch.
FI872733A (fi) Farmaceutiska kompositioner.
FI872313A (fi) Farmaceutiska kompositioner.
ES2019634B3 (es) Terapia con clorfeniramina.
LV10870A (lv) Jauni fosfolipidu atvasinajumi
NO873628D0 (no) 2,3-dihydro-1h-fenalen-2-amino-forbindelser som antipsykotiske legemidler.
NO871229D0 (no) Farmasoeytisk blanding som inneholder oksazepam.
IT8722591A0 (it) Formulazione farmaceutica contenente gemfibrozilmicroincapsulato.
NO874743D0 (no) Terapeutiske blandinger for veterinaerbruk.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 248062

Country of ref document: ES